Robert S. Kania
Pfizer (United States)(US)RG Biopharma (United States)(US)CTI BioPharma (Italy)(IT)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Chemical Synthesis and Analysis, PI3K/AKT/mTOR signaling in cancer, Angiogenesis and VEGF in Cancer, Cancer Treatment and Pharmacology
Most-Cited Works
- → Peptoids: a modular approach to drug discovery.(1992)936 cited
- → Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)(2011)909 cited
- → Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3(2008)623 cited
- → Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations(2014)574 cited
- → Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors(2012)548 cited